541 related articles for article (PubMed ID: 21914219)
1. Suppression of apoptosis inhibitor c-FLIP selectively eliminates breast cancer stem cell activity in response to the anti-cancer agent, TRAIL.
Piggott L; Omidvar N; Martí Pérez S; French R; Eberl M; Clarkson RW
Breast Cancer Res; 2011 Sep; 13(5):R88. PubMed ID: 21914219
[TBL] [Abstract][Full Text] [Related]
2. Acquired Resistance of ER-Positive Breast Cancer to Endocrine Treatment Confers an Adaptive Sensitivity to TRAIL through Posttranslational Downregulation of c-FLIP.
Piggott L; Silva A; Robinson T; Santiago-Gómez A; Simões BM; Becker M; Fichtner I; Andera L; Young P; Morris C; Barrett-Lee P; Alchami F; Piva M; Vivanco MD; Clarke RB; Gee J; Clarkson R
Clin Cancer Res; 2018 May; 24(10):2452-2463. PubMed ID: 29363524
[No Abstract] [Full Text] [Related]
3. Cytoplasmic levels of cFLIP determine a broad susceptibility of breast cancer stem/progenitor-like cells to TRAIL.
French R; Hayward O; Jones S; Yang W; Clarkson R
Mol Cancer; 2015 Dec; 14():209. PubMed ID: 26667821
[TBL] [Abstract][Full Text] [Related]
4. Roscovitine sensitizes breast cancer cells to TRAIL-induced apoptosis through a pleiotropic mechanism.
Ortiz-Ferrón G; Yerbes R; Eramo A; López-Pérez AI; De Maria R; López-Rivas A
Cell Res; 2008 Jun; 18(6):664-76. PubMed ID: 18458681
[TBL] [Abstract][Full Text] [Related]
5. Control of FLIP(L) expression and TRAIL resistance by the extracellular signal-regulated kinase1/2 pathway in breast epithelial cells.
Yerbes R; López-Rivas A; Reginato MJ; Palacios C
Cell Death Differ; 2012 Dec; 19(12):1908-16. PubMed ID: 22722337
[TBL] [Abstract][Full Text] [Related]
6. The sesquiterpene lactone eupatolide sensitizes breast cancer cells to TRAIL through down-regulation of c-FLIP expression.
Lee J; Hwangbo C; Lee JJ; Seo J; Lee JH
Oncol Rep; 2010 Jan; 23(1):229-37. PubMed ID: 19956887
[TBL] [Abstract][Full Text] [Related]
7. Flavopiridol induces cellular FLICE-inhibitory protein degradation by the proteasome and promotes TRAIL-induced early signaling and apoptosis in breast tumor cells.
Palacios C; Yerbes R; López-Rivas A
Cancer Res; 2006 Sep; 66(17):8858-69. PubMed ID: 16951203
[TBL] [Abstract][Full Text] [Related]
8. Itch/AIP4-independent proteasomal degradation of cFLIP induced by the histone deacetylase inhibitor SAHA sensitizes breast tumour cells to TRAIL.
Yerbes R; López-Rivas A
Invest New Drugs; 2012 Apr; 30(2):541-7. PubMed ID: 21107885
[TBL] [Abstract][Full Text] [Related]
9. Interleukin-8 signaling attenuates TRAIL- and chemotherapy-induced apoptosis through transcriptional regulation of c-FLIP in prostate cancer cells.
Wilson C; Wilson T; Johnston PG; Longley DB; Waugh DJ
Mol Cancer Ther; 2008 Sep; 7(9):2649-61. PubMed ID: 18790747
[TBL] [Abstract][Full Text] [Related]
10. The WWP1 ubiquitin E3 ligase increases TRAIL resistance in breast cancer.
Zhou Z; Liu R; Chen C
Int J Cancer; 2012 Apr; 130(7):1504-10. PubMed ID: 21480222
[TBL] [Abstract][Full Text] [Related]
11. Development of acquired resistance to lapatinib may sensitise HER2-positive breast cancer cells to apoptosis induction by obatoclax and TRAIL.
Eustace AJ; Conlon NT; McDermott MSJ; Browne BC; O'Leary P; Holmes FA; Espina V; Liotta LA; O'Shaughnessy J; Gallagher C; O'Driscoll L; Rani S; Madden SF; O'Brien NA; Ginther C; Slamon D; Walsh N; Gallagher WM; Zagozdzon R; Watson WR; O'Donovan N; Crown J
BMC Cancer; 2018 Oct; 18(1):965. PubMed ID: 30305055
[TBL] [Abstract][Full Text] [Related]
12. C-FLIP(L) contributes to TRAIL resistance in HER2-positive breast cancer.
Zang F; Wei X; Leng X; Yu M; Sun B
Biochem Biophys Res Commun; 2014 Jul; 450(1):267-73. PubMed ID: 24909691
[TBL] [Abstract][Full Text] [Related]
13. Selective inhibition of FLICE-like inhibitory protein expression with small interfering RNA oligonucleotides is sufficient to sensitize tumor cells for TRAIL-induced apoptosis.
Siegmund D; Hadwiger P; Pfizenmaier K; Vornlocher HP; Wajant H
Mol Med; 2002 Nov; 8(11):725-32. PubMed ID: 12520089
[TBL] [Abstract][Full Text] [Related]
14. Suppression of HSP70 expression sensitizes NSCLC cell lines to TRAIL-induced apoptosis by upregulating DR4 and DR5 and downregulating c-FLIP-L expressions.
Zhuang H; Jiang W; Zhang X; Qiu F; Gan Z; Cheng W; Zhang J; Guan S; Tang B; Huang Q; Wu X; Huang X; Jiang W; Hu Q; Lu M; Hua ZC
J Mol Med (Berl); 2013 Feb; 91(2):219-35. PubMed ID: 22948392
[TBL] [Abstract][Full Text] [Related]
15. Progesterone induces apoptosis in TRAIL-resistant ovarian cancer cells by circumventing c-FLIPL overexpression.
Syed V; Mukherjee K; Godoy-Tundidor S; Ho SM
J Cell Biochem; 2007 Oct; 102(2):442-52. PubMed ID: 17393432
[TBL] [Abstract][Full Text] [Related]
16. Down-regulation of intracellular anti-apoptotic proteins, particularly c-FLIP by therapeutic agents; the novel view to overcome resistance to TRAIL.
Hassanzadeh A; Farshdousti Hagh M; Alivand MR; Akbari AAM; Shams Asenjan K; Saraei R; Solali S
J Cell Physiol; 2018 Oct; 233(10):6470-6485. PubMed ID: 29741767
[TBL] [Abstract][Full Text] [Related]
17. F-box protein 10, an NF-κB-dependent anti-apoptotic protein, regulates TRAIL-induced apoptosis through modulating c-Fos/c-FLIP pathway.
Ge R; Wang Z; Zeng Q; Xu X; Olumi AF
Cell Death Differ; 2011 Jul; 18(7):1184-95. PubMed ID: 21252908
[TBL] [Abstract][Full Text] [Related]
18. α-TEA induces apoptosis of human breast cancer cells via activation of TRAIL/DR5 death receptor pathway.
Yu W; Tiwary R; Li J; Park SK; Jia L; Xiong A; Simmons-Menchaca M; Sanders BG; Kline K
Mol Carcinog; 2010 Nov; 49(11):964-73. PubMed ID: 20886583
[TBL] [Abstract][Full Text] [Related]
19. Programmed cell death 4 (PDCD4) mediates the sensitivity of gastric cancer cells to TRAIL-induced apoptosis by down-regulation of FLIP expression.
Wang W; Zhao J; Wang H; Sun Y; Peng Z; Zhou G; Fan L; Wang X; Yang S; Wang R; Fang D
Exp Cell Res; 2010 Sep; 316(15):2456-64. PubMed ID: 20595005
[TBL] [Abstract][Full Text] [Related]
20. Gli2 silencing enhances TRAIL-induced apoptosis and reduces tumor growth in human hepatoma cells in vivo.
Zhang DW; Li HY; Lau WY; Cao LQ; Li Y; Jiang XF; Yang XW; Xue P
Cancer Biol Ther; 2014; 15(12):1667-76. PubMed ID: 25535898
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
